Nov 28, 2019
WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products
Nov 24, 2019
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 11, 2019
Big Pharma Gaining Increased Interest in Fighting Cancer With Oncolytic Virus Therapies
Nov 11, 2019
DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 06, 2019
Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
Sep 16, 2019
SillaJen Defending Position Relating to Recent Sale of Stock by Employee
Sep 02, 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Aug 14, 2019
Western Oncolytics Appoints Helena Chaye as Chief Executive Officer
Aug 02, 2019
SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC
Jun 17, 2019
Valo Therapeutics Appoints Michael Stein as Chief Executive Officer
Jun 06, 2019
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)
Jun 05, 2019
Oncolytic Virotherapies Analytical Tool: 85 Companies Developing 150 Virus Drugs - 113 are in Active Development in Cancer Across 40 Different Targets
Jun 03, 2019
Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination
May 28, 2019
Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells
May 23, 2019
Targovax to Fully Focus on ONCOS Oncolytic Virus Program
May 21, 2019
Western Oncolytics Awarded SBIR Grant to Fund the Company's Next Generation Oncolytic Virus Therapy
Apr 30, 2019
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy
Apr 01, 2019
Candel Therapeutics Completes $22.5 Million Series C Preferred Stock Offering
Mar 26, 2019
BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
Mar 21, 2019
Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials